"rationale","id","label","name","uuid:ID","description","instanceType"
"The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyDesign_1","","Study Design 1","048526eb-deb8-4235-a460-753a5f2d3778","The main design for the study","StudyDesign"
